Cytokinetics (CYTK) Misses Q2 EPS by 20c, misses on revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $62.33 -0.84%
EPS Growth %: +43.1%
Financial Fact:
General and administrative: 7.22M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: +43.1%
Financial Fact:
General and administrative: 7.22M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.34), $0.20 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $870 thousand versus the consensus estimate of $5.67 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- National Bankshares Inc (NKSH) Misses Q3 EPS by 12c
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
